Clinical trials in neuro-oncology

被引:5
作者
Batchelor, T
Stanley, K
Andersen, J
机构
[1] Massachusetts Gen Hosp, Brain Tumor Ctr, Dept Neurol, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
关键词
D O I
10.1097/00019052-200112000-00003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Clinical trials are prospective scientific studies involving human participants and form the basis for identifying new treatments for diseases like brain tumors. A clinical trial should be designed to provide definitive results for a study question. Therefore, investigators should understand the principles underlying the design, execution and analysis of clinical trials. In addition to the application of basic principles germane to the design of all clinical trials, studies in neuro-oncology also involve unique challenges in case definition, selection of endpoints and definition of response. This review begins with enumeration of the basic principles of clinical trial design including reduction of bias and variability, and concludes with a review of study design factors of particular relevance for neuro-oncology. Curr Opin Neurol 14:689-694. (C) 2001 Lippincott Williams Wilkins.
引用
收藏
页码:689 / 694
页数:6
相关论文
共 31 条
[1]   Pretreatment factors predict overall survival for patients with low-grade glioma: A recursive partitioning analysis [J].
Bauman, G ;
Lote, K ;
Larson, D ;
Stalpers, L ;
Leighton, C ;
Fisher, B ;
Wara, W ;
MacDonald, D ;
Stitt, L ;
Cairncross, JG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (04) :923-929
[2]   WHY DATA-BASES SHOULD NOT REPLACE RANDOMIZED CLINICAL-TRIALS [J].
BYAR, DP .
BIOMETRICS, 1980, 36 (02) :337-342
[3]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[4]   RECURSIVE PARTITIONING ANALYSIS OF PROGNOSTIC FACTORS IN 3 RADIATION-THERAPY ONCOLOGY GROUP MALIGNANT GLIOMA TRIALS [J].
CURRAN, WJ ;
SCOTT, CB ;
HORTON, J ;
NELSON, JS ;
WEINSTEIN, AS ;
FISCHBACH, AJ ;
CHANG, CH ;
ROTMAN, M ;
ASBELL, SO ;
KRISCH, RE ;
NELSON, DF .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (09) :704-710
[5]   Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions [J].
Fetell, MR ;
Grossman, SA ;
Fisher, JD ;
Erlanger, B ;
Rowinsky, E ;
Stockel, J ;
Piantadosi, S .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) :3121-3128
[6]   SELECTION BIAS, SURVIVAL, AND BRACHYTHERAPY FOR GLIOMA [J].
FLORELL, RC ;
MACDONALD, DR ;
IRISH, WD ;
BERNSTEIN, M ;
LEIBEL, SA ;
GUTIN, PH ;
CAIRNCROSS, JG .
JOURNAL OF NEUROSURGERY, 1992, 76 (02) :179-183
[7]  
GILBERT MR, 2000, P AN M AM SOC CLIN, V19, pA161
[8]   Chemotherapy response criteria in malignant glioma [J].
Grant, R ;
Liang, BC ;
Slattery, J ;
Greenberg, HS ;
Junck, L .
NEUROLOGY, 1997, 48 (05) :1336-1340
[9]   Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants [J].
Grossman, SA ;
Hochberg, F ;
Fisher, J ;
Chen, TL ;
Kim, L ;
Gregory, R ;
Grochow, LB ;
Piantadosi, S .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (02) :118-126
[10]   Measuring bias in uncontrolled brain tumor trials - to randomize or not to randomize? [J].
Irish, WD ;
Macdonald, DR ;
Cairncross, JG .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1997, 24 (04) :307-312